Principia Biopharma Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

SEC Insider

$512.8M

316 transactions

Summary

Principia Biopharma Inc. is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $69.5MSales: $53.9M40 insiders

Date	Insider	Type	Value
2020-09-28	Babler Martin(President, CEO)	U	$3.9M
2020-09-28	Babler Martin(President, CEO)	U	$1.8M
2020-09-28	Babler Martin(President, CEO)	U	$102K
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Babler Martin(President, CEO)	D	—
2020-09-28	Goldstein David M(Chief Scientific Officer)	D	—
2020-09-28	Goldstein David M(Chief Scientific Officer)	D	—
2020-09-28	Goldstein David M(Chief Scientific Officer)	D	—
2020-09-28	Goldstein David M(Chief Scientific Officer)	D	—
2020-09-28	Goldstein David M(Chief Scientific Officer)	D	—
2020-09-28	Goldstein David M(Chief Scientific Officer)	D	—
2020-09-28	Goldstein David M(Chief Scientific Officer)	D	—

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Principia Biopharma Inc. — Contributions, Lobbying & Contracts | Poliscope